Ribociclib succinate is under clinical development by Novartis and currently in Phase II for Triple-Negative Breast Cancer (TNBC).

A panelist discusses how the phase 2 ELECTRA trial studies elacestrant in combination with ribociclib as first-line therapy for ER+/HER2– advanced breast cancer in postmenopausal women.

Ribociclib plus endocrine therapy shows PFS benefit in luminal B/HER2E breast cancer subtypes compared to chemotherapy, especially with low immune-related gene expression. Ribociclib (Kisqali) and ...

What was the safety profile of ribociclib (Kisqali) in the phase 3 NATALEE trial (NCT03701334)? JHAVERI: Neutropenia is the most common toxicity. All-grade neutropenia [occurred in] 62% [of patients] ...

The most frequently used standard treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer patients consists of a CDK4/6 ...

A phase 1 trial of camizestrant with ribociclib appears safe and effective in patients with ER+/HER2- advanced breast cancer. Treatment with camizestrant plus ribociclib (Kisqali) induced a median ...

Camizestrant with Kisqali is effective and tolerable for ER-positive/HER2-negative advanced breast cancer, with a median PFS of 8.1 months for both doses. Objective ...

Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients ...

ribociclib, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. Results as of September 25, 2024 ...

Detailed price information for Olema Pharmaceuticals Inc (OLMA-Q) from The Globe and Mail including charting and trades.

Kisqali (ribociclib), a CDK4/6 inhibitor, has made significant strides in the treatment of HR-positive, HER2-negative early breast cancer, although several follow-up studies are being conducted to ...